Phase 3
Completed N=136
Midodrine for the Treatment of Refractory Hypotension
Source: ClinicalTrials.gov NCT01531959 ↗Enrolled (actual)
136
Serious AEs
0.8%
Results posted
Sep 2019
Primary outcomePrimary: Time Until Discontinuation of IV Vasopressors — 23.5; 22.5 hours
◆ Published Evidence
Established
38citations · ~4 / year
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Summary
We hypothesize that midodrine treatment of refractory hypotension in patients otherwise ready for discharge from the ICU shortens duration of receiving IV vasopressors and SICU length of stay without increasing MGH length of stay or putting the patient at risk of being readmitted to an ICU.
Linked Publications
-
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time Until Discontinuation of IV Vasopressors |
23.5; 22.5 | — |
| SECONDARY ICU Length of Stay |
6.0; 6.0 | — |
| SECONDARY Hospital Length of Stay |
11.0; 14.0 | — |
| SECONDARY Rates of ICU Readmission |
1; 3 | — |
| SECONDARY Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias |
12; 3 | — |
Eligibility Criteria
Inclusion Criteria
- At least 18 years of age
- Admitted to the SICU
- Requiring IV vasopressors at a rate of less than 100 mcg/min of phenylephrine, or 8 mcg/min of norepinephrine, or 60 mcg/min of metaraminol; and unable to wean for more than 24 hours while still maintaining desired blood pressure goal
Exclusion Criteria
- Inadequate tissue oxygenation
- Liver failure
- Renal failure
- Hypovolemic shock or hypotension due to adrenal insufficiency
- Pregnancy
- Severe organic heart disease
- Urinary retention
- Pheochromocytoma
- Thyrotoxicosis
- Midodrine as pre-admission medication
- Any known allergies to midodrine
- Enrollment in another clinical trial
Data sourced from ClinicalTrials.gov (NCT01531959) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.